Calcimedica announces private placement of up to approximately $55 million

$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million upfront net proceeds to provide funds to expand auxora™ clinical development to include planned phase 2 acute kidney injury (aki) trial expected to begin in 1h 2024 aggregate net proceeds (assuming exercise of all accompanying warrants) expected to be sufficient to fund calcimedica through subsequent, potentially pivotal, clinical trials and other work in calcimedica's acute pancreatitis (ap) and aki programs la jolla, calif. , jan. 22, 2024 /prnewswire/ -- calcimedica, inc. (calcimedica or the company) (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that it has entered into a securities purchase agreement with new and existing investors to raise up to approximately $55 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants.
CALC Ratings Summary
CALC Quant Ranking